<DOC>
	<DOCNO>NCT00002211</DOCNO>
	<brief_summary>The purpose study see safe effective give combination three four anti-HIV drug HIV-infected patient . The drug use study delavirdine ( DLV ) , nelfinavir ( NLF ) , didanosine ( ddI ) , stavudine ( d4T ) .</brief_summary>
	<brief_title>Safety Effectiveness Giving Combinations Three Four Anti-HIV Drugs HIV-Infected Patients</brief_title>
	<detailed_description>This multicenter , open-label study . Patients stratify HIV-1 RNA level ( 20,000 200,000 copies/ml great 200,000 copies/ml ) . Patients equally randomize one four group receive antiretroviral therapy 24 week . Group 1 receives delavirdine ( DLV ) plus nelfinavir ( NFV ) plus stavudine ( d4T ) . Group 2 receive DLV plus NFV plus didanosine ( ddI ) . Group 3 receive NFV plus d4T plus ddI . Group 4 receive DLV plus NFV plus d4T plus ddI . Patients evaluated drug safety viral burden . Patients may opt continue study 24 additional week , discretion investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are least 18 year old . Are HIVpositive . Have CD4 count least 50 cells/mm3 . Have viral load least 20,000 copies/ml . Exclusion Criteria You eligible study : Have take d4T . Have take protease inhibitor , include NFV . Have take nonnucleoside reverse transcriptase inhibitor . Have take ddI 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>